Physician profile
Raj Devarajan
NPI 1508926668
$3,687.70
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,187 · 2020: $233 · 2021: $55.05 · 2022: $1,872 · 2023: $298 · 2024: $42.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,035.16 | 2019-2022 | |
| Abbvie INC. | $791.72 | 2019-2024 | Rinvoq, Linzess, Skyrizi |
| Pfizer INC. | $238.25 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $127.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $114.12 | 2019-2020 | |
| Janssen Biotech, INC. | $107.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $85.52 | 2019-2020 | |
| Allergan, INC. | $42.58 | 2019 | |
| Ucb, INC. | $26.27 | 2019 | |
| Celgene Corporation | $24.26 | 2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $18.96 | 2019 | |
| Echosens North America, INC. | $18.46 | 2022 | |
| Braintree Laboratories, INC. | $16.13 | 2019 | |
| Endo Pharmaceuticals INC. | $15.18 | 2019 | |
| Alfasigma USA, INC. | $14.77 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raj Devarajan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.